MiR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer

Oncology Research

Volumn 21, Issue 6, 2014, Pages 353-363

  Qin, Yong ^a,b   Dang, Xiaoyan ^c   Li, Wei ^a   Ma, Qingyong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; FSCN1; Invasion; MicroRNA 133a; Pancreatic cancer; Proliferation

Indexed keywords

ACTIN BINDING PROTEIN; MESSENGER RNA; MICRORNA 133A; PROTEIN FSCN1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CARRIER PROTEIN; FSCN1 PROTEIN, HUMAN; MICRORNA; MIRN133 MICRORNA, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR VOLUME; UPREGULATION; 3' UNTRANSLATED REGION; AGED; ANIMAL; BINDING SITE; CANCER GRADING; CELL MOTION; CELL TRANSFORMATION; CHEMISTRY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; XENOGRAFT;

3' UNTRANSLATED REGIONS; ADULT; AGED; ANIMALS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HUMANS; MALE; MICROFILAMENT PROTEINS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROGNOSIS; RNA INTERFERENCE; TUMOR BURDEN;

EID: 84911424189     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504014X14024160459122     Document Type: Article

References (40)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA. Cancer J. Clin. 59:225-249; 2009.
2. Niederhuber, J. E.; Brennan, M. F.; Menck, H. R. The National Cancer Data Base report on pancreatic cancer. Cancer 76:1671-1677; 1995.
3. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA. Cancer J. Clin. 60:277-300; 2010.
4. Jones, S.; Zhang, X.; Parsons, D. W.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S. M.; Fu, B.; Lin, M. T.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.; Goggins, M.; Maitra, A.; Iacobuzio- Donahue, C.; Eshleman, J. R.; Kern, S. E.; Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806; 2008.
5. Osman, A. MicroRNAs in health and disease - Basic science and clinical applications. Clin. Lab. 58:393-402; 2012.
6. Bartel, D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297; 2004.
7. Zhang, B.; Pan, X.; Cobb, G. P.; Anderson, T. A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302: 1-12; 2007.
8. Dieckmann, K. P.; Spiekermann, M.; Balks, T.; Flor, I.; Loning, T.; Bullerdiek, J.; Belge, G. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br. J. Cancer 107:1754-1760; 2012.
9. Takahashi, M.; Cuatrecasas, M.; Balaguer, F.; Hur, K.; Toiyama, Y.; Castells, A.; Boland, C. R.; Goel, A. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One 7:e46684; 2012.
10. Song, T.; Xia, W.; Shao, N.; Zhang, X.; Wang, C.; Wu, Y.; Dong, J.; Cai, W.; Li, H. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac. J. Cancer Prev. 11:905-911; 2010.
11. Nohata, N.; Hanazawa, T.; Kikkawa, N.; Mutallip, M.; Fujimura, L.; Yoshino, H.; Kawakami, K.; Chiyomaru, T.; Enokida, H.; Nakagawa, M.; Okamoto, Y.; Seki, N. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int. J. Oncol. 38:209-217; 2011.
12. Rao, P. K.; Missiaglia, E.; Shields, L.; Hyde, G.; Yuan, B.; Shepherd, C. J.; Shipley, J.; Lodish, H. F. Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J. 24:3427-3437; 2010.
13. Kano, M.; Seki, N.; Kikkawa, N.; Fujimura, L.; Hoshino, I.; Akutsu, Y.; Chiyomaru, T.; Enokida, H.; Nakagawa, M.; Matsubara, H. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int. J. Cancer 127:2804-2814; 2010.
14. Sarver, A. L.; French, A. J.; Borralho, P. M.; Thayanithy, V.; Oberg, A. L.; Silverstein, K. A.; Morlan, B. W.; Riska, S. M.; Boardman, L. A.; Cunningham, J. M.; Subramanian, S.; Wang, L.; Smyrk, T. C.; Rodrigues, C. M.; Thibodeau, S. N.; Steer, C. J. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9:401; 2009.
15. Wong, T. S.; Liu, X. B.; Chung-Wai Ho, A.; Po-Wing Yuen, A.; Wai-Man Ng, R.; Ignace Wei, W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 123:251-257; 2008.
16. Kawakami, K.; Enokida, H.; Chiyomaru, T.; Tatarano, S.; Yoshino, H.; Kagara, I.; Gotanda, T.; Tachiwada, T.; Nishiyama, K.; Nohata, N.; Seki, N.; Nakagawa, M. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur. J. Cancer 48:827-836; 2012.
17. Nohata, N.; Hanazawa, T.; Enokida, H.; Seki, N. microRNA- 1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers. Oncotarget 3:9-21; 2012.
18. Hashimoto, Y.; Skacel, M.; Adams, J. C. Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker? Int. J. Biochem. Cell. Biol. 37:1787- 1804; 2005.
19. Kureishy, N.; Sapountzi, V.; Prag, S.; Anilkumar, N.; Adams, J. C. Fascins, and their roles in cell structure and function. Bioessays 24:350-361; 2002.
20. Yamashiro, S.; Yamakita, Y.; Ono, S.; Matsumura, F. Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell 9:993-1006; 1998.
21. Darnel, A. D.; Behmoaram, E.; Vollmer, R. T.; Corcos, J.; Bijian, K.; Sircar, K.; Su, J.; Jiao, J.; Alaoui-Jamali, M. A.; Bismar, T. A. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin. Cancer Res. 15:1376-1383; 2009.
22. Chiyomaru, T.; Enokida, H.; Tatarano, S.; Kawahara, K.; Uchida, Y.; Nishiyama, K.; Fujimura, L.; Kikkawa, N.; Seki, N.; Nakagawa, M. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br. J. Cancer 102:883-891; 2010.
23. Zhang, H.; Xu, L.; Xiao, D.; Xie, J.; Zeng, H.; Cai, W.; Niu, Y.; Yang, Z.; Shen, Z.; Li, E. Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J. Clin. Pathol. 59:958-964; 2006.
24. Hashimoto, Y.; Shimada, Y.; Kawamura, J.; Yamasaki, S.; Imamura, M. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67:262-270; 2004.
25. Pelosi, G.; Pastorino, U.; Pasini, F.; Maissoneuve, P.; Fraggetta, F.; Iannucci, A.; Sonzogni, A.; De Manzoni, G.; Terzi, A.; Durante, E.; Bresaola, E.; Pezzella, F.; Viale, G. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br. J. Cancer 88:537- 547; 2003.
26. Jawhari, A. U.; Buda, A.; Jenkins, M.; Shehzad, K.; Sarraf, C.; Noda, M.; Farthing, M. J.; Pignatelli, M.; Adams, J. C. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am. J. Pathol. 162:69-80; 2003.
27. Grothey, A.; Hashizume, R.; Ji, H.; Tubb, B. E.; Patrick, C. W., Jr.; Yu, D.; Mooney, E. E.; McCrea, P. D. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19:4864-4875; 2000.
28. Lin, C. K.; Chao, T. K.; Yu, C. P.; Yu, M. H.; Jin, J. S. The expression of six biomarkers in the four most common ovarian cancers: Correlation with clinicopathological parameters. APMIS 117:162-175; 2009.
29. Maitra, A.; Adsay, N. V.; Argani, P.; Iacobuzio-Donahue, C.; De Marzo, A.; Cameron, J. L.; Yeo, C. J.; Hruban, R. H. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod. Pathol. 16:902-912; 2003.
30. Wu, Z. S.; Wang, C. Q.; Xiang, R.; Liu, X.; Ye, S.; Yang, X. Q.; Zhang, G. H.; Xu, X. C.; Zhu, T.; Wu, Q. Loss of miR- 133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 12:51; 2012.
31. Moriya, Y.; Nohata, N.; Kinoshita, T.; Mutallip, M.; Okamoto, T.; Yoshida, S.; Suzuki, M.; Yoshino, I.; Seki, N. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J. Hum. Genet. 57:38-45; 2012.
32. Missiaglia, E.; Shepherd, C. J.; Patel, S.; Thway, K.; Pierron, G.; Pritchard-Jones, K.; Renard, M.; Sciot, R.; Rao, P.; Oberlin, O.; Delattre, O.; Shipley, J. MicroRNA- 206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br. J. Cancer 102:1769-1777; 2010.
33. Nohata, N.; Hanazawa, T.; Kikkawa, N.; Sakurai, D.; Sasaki, K.; Chiyomaru, T.; Kawakami, K.; Yoshino, H.; Enokida, H.; Nakagawa, M.; Okamoto, Y.; Seki, N. Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. Int. J. Oncol. 39:1099-1107; 2011.
34. Kojima, S.; Chiyomaru, T.; Kawakami, K.; Yoshino, H.; Enokida, H.; Nohata, N.; Fuse, M.; Ichikawa, T.; Naya, Y.; Nakagawa, M.; Seki, N. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br. J. Cancer 106:405-413; 2012.
35. Yoshino, H.; Chiyomaru, T.; Enokida, H.; Kawakami, K.; Tatarano, S.; Nishiyama, K.; Nohata, N.; Seki, N.; Nakagawa, M. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br. J. Cancer 104:808-818; 2011.
36. Ruan, K.; Fang, X.; Ouyang, G. MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer. Lett. 285: 116-126; 2009.
37. Chiyomaru, T.; Enokida, H.; Kawakami, K.; Tatarano, S.; Uchida, Y.; Kawahara, K.; Nishiyama, K.; Seki, N.; Nakagawa, M. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol. Oncol. 30:434-443; 2012.
38. Hashimoto, Y.; Ito, T.; Inoue, H.; Okumura, T.; Tanaka, E.; Tsunoda, S.; Higashiyama, M.; Watanabe, G.; Imamura, M.; Shimada, Y. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin. Cancer Res. 11:2597-2605; 2005.
39. Zhou, L.; Zhang, R.; Zhang, L.; Sun, Y.; Yao, W.; Zhao, A.; Li, J.; Yuan, Y. Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer. Cancer. Sci. 104:423-430; 2013.
40. Salem, A. F.; Bonuccelli, G.; Bevilacqua, G.; Arafat, H.; Pestell, R. G.; Sotgia, F.; Lisanti, M. P. Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelialmesenchymal transition. Cell Cycle 10:3692-3700; 2011.